Hot Topics

Poll

Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?
Because it is easier
21%
Because it is less damaging for campaign donations
6%
Because the pressure from patent owners is too great
29%
Because it is better for one's career
1%
Because patients do not really matter
3%
All of the above
30%
None of the above
9%
Total votes: 302

NIH acknowledges KEI/UACT request to use royalty-free or march-in rights on Xtandi

On February 8, 2016, the National Institutes of Health (NIH) responded to Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment’s (UACT) letter requesting that the federal government exercise its authority under the Bayh-Dole Act to break patents on an expensive prostate cancer drug.

Feasibility study on a TDR pooled fund for R&D to be released on 20 February 2016

In May 2014, the 67th World Health Assembly (WHA) of the World Health Organization (WHO) passed Decision WHA67(15) providing WHO the mandate to explore the feasibility of creating a voluntary pooled fund fund on R&D hosted by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). The Decision outlined three principles guiding the consideration of the pooled fund:

SAVE THE DATE - 26 January 2016: Implications of the TPP and RCEP on Universal Health Coverage

Implications of the Trans Pacific Partnership (TPP) and Regional Comprehensive Economic Partnership (RCEP) on Universal Health Coverage

Knowledge Ecology International

26 January 2016
9 AM to 12:30 PM
Lotus Suite 3. 22nd Floor
Bangkok Convention Centre
Bangkok, Thailand

Xtandi 2016 March-In Request

Today Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) petitioned the Department of Health and Human Services, the Department of Defense, and the National Institutes of Health, asking that they exercise federal "march-in" rights to end the monopoly on an expensive prostate cancer drug, enzalutamide, marketed as Xtandi by Astellas, a Japanese pharmaceutical company.

Xtandi was invented at UCLA on federal grants from the NIH and DoD.

Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutes

Washington, DC — On January 11, 2016, Knowledge Ecology International joined Public Knowledge and the American Library Association in an amicus curiae brief that argued that the contents of model laws, once enacted into statute, cannot be protected by copyright. The brief was filed with the U.S. District Court for the District of Columbia in the case of ASTM International v. Public.Resource.Org.

51 members of Congress have asked the NIH to use March-In rights to rein in high drug prices

This was the release from Representative Doggett's office:

FOR IMMEDIATE RELEASE
January 11, 2016

Contact:
Leslie Tisdale, (202) 225-4865
Over 50 Members of Congress to Obama Administration:
Help End Drug Price Gouging Now

WHO's evaluation of the global strategy and plan of action on public health, innovation and intellectual property

In May 2008, the 61st World Health Assembly (WHA) of the World Health Organization (WHO) adopted the seminal global strategy and plan of action on public health, innovation and intellectual property.

As stated in its aim, the global strategy on public health, innovation and intellectual property serves to

FDA approves 45 new drugs. 47 percent qualify for 50 percent Orphan Drug tax credit

In calendar year 2015, FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs). This is a large number of approvals.

KEI's December 19, 2015 submission to the US ITC regarding the TPP

Attached here is a KEI submission to the US ITC for the January hearing of the

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, DC
Investigation No. TPA-105-001
Trans-Pacific Partnership Agreement: Likely Impact on the U.S. Economy and on Specific Industry Sectors

Our earlier, related testimony on trade agreements was here: http://keionline.org/node/2370

The UK's rebates on drug sales, and introducing the budget constraint into pricing models

Under the UK's Pharmaceutical Price Regulation Scheme (PPRS), drug companies will make rebates of about £550 million in 2016, according to this story.

SAVE THE DATE - 16 December 2015 - KEI breakout session on A WTO Agreement on the Supply of Social Goods

On Wednesday, 16 December 2015, at the Fourth Global Congress on Intellectual Property and the Public Interest (National Law University, Delhi, India), Knowledge Ecology International (KEI) will convene a breakout session (led by Jamie Love, Director, KEI) on a WTO Agreement on the Supply of Social Goods.

SCCR 31 Chair's Conclusion

Chair's Conclusions

conclusions.png
MICHELE WOODS: Standing Committee on Copyright and Related Rights, 31st session, Geneva, December 7 to 11, 2015. Summary by the Chair.

Agenda item 1. Opening of the session. The 31st session of the Standing Committee on Copyright and Related Rights SCCR or Committee was opened by Mr. Francis Gurry, Director General who welcomed the participants and opened agenda item 2.
Ms. Michele Woods, WIPO, acted as secretary.

SCCR 31 Chair's proposal for future work and conclusions

The Chair proposed an intersessional on broadcasting and regional meetings regarding Libraries and Archives. This was supported by Asia, Grulac and Africa (but Africa wanted to include education and research institution) and rejected by Group B. The decision will be made at the next SCCR, SCCR 32 possibly May 9-13 2016.

SCCR 31: KEI Statement on Droit de Suite/Resale Rights

Day 5 of SCCR 31, December 11, 2015

thiruresale_0.png

Thank you Mr Chair.

We welcome the proposal tabled by Senegal and the Congo to include the droit de suite, the artist resale right, in this Committee’s agenda for future work.

I would like to refer to the Directive mentioned by the Commission, Directive 2001/84/EC which came into force on 1 January 2006:

Syndicate content